Presentation of the results from AB8939 preclinical program in AML in EHA 2020 Annual Congress

10/06/2020 – AB Science will present results from AB8939 preclinical program in acute myeloid leukemia at the EHA 2020 Annual Congress Related Posts Boursorama interview of Alain Moussy, CEO of AB Science 23 December 2020 Capital raise for a total amount of 15 million euros 21 December 2020 Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease 18 December 2020 Masitinib in Alzheimer’s Disease Webcast Presentation 17 December 2020 Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020 17 December 2020 Corrective press release regarding adverse events information from study AB09004 17 December 2020 Search Recent Posts AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026 AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development AB Science announces the successful completion of a EUR 2.3 million private placement AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML AB SCIENCE HEADQUARTER 3, Avenue George V – 75008 PARIS – FRANCE Tel. : +33 (0)1 47 20 00 14 Fax. : +33 (0)1 47 20 24 11 GENERAL INQUIRIES [email protected] PRODUCT INQUIRIES [email protected] JOB INQUIRIES [email protected] CLINICAL INQUIRIES [email protected] MEDIA / FINANCIAL INQUIRIES [email protected] PHARMACOVIGILANCE [email protected] Fax : +33 1 47 20 10 82

The release as fetched from its publisher. ab-science.com ↗